Whitehawk Therapeutics (WHWK) CEO awarded 51,021 shares in new stock grant

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. director and chief executive officer David James Lennon reported an equity compensation grant of Common Stock. He acquired 51,021 shares at an indicated value of $3.92 per share as a grant, bringing his direct holdings to 569,643 shares after the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lennon David James

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	51,021	$3.92	$200K

Holdings After Transaction: Common Stock — 569,643 shares (Direct, null)

Footnotes (1)

Key Figures

Shares granted: 51,021 shares Grant value per share: $3.92 per share Shares held after grant: 569,643 shares +2 more

5 metrics

Shares granted 51,021 shares Common Stock grant to CEO David James Lennon

Grant value per share $3.92 per share Indicated value for the 51,021-share grant

Shares held after grant 569,643 shares CEO direct holdings following the transaction

Transaction date May 14, 2026 Date of reported Common Stock grant

Transaction code A Grant, award, or other acquisition of Common Stock

Key Terms

Common Stock, Grant, award, or other acquisition, direct holdings

3 terms

Common Stock financial

"He acquired 51,021 shares at an indicated value of $3.92 per share as a grant"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"The transaction was coded as a grant, award, or other acquisition"

direct holdings financial

"bringing his direct holdings to 569,643 shares after the transaction"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lennon David James

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		51,021	A	$3.92	569,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Stephen Rodin, as Attorney-in-Fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did WHWK CEO David James Lennon report?

David James Lennon reported receiving a grant of 51,021 shares of Whitehawk Therapeutics Common Stock. The transaction was coded as a grant or award, indicating equity compensation rather than an open-market purchase or sale.

Was the WHWK CEO transaction a buy or a grant of shares?

The transaction was a grant of shares, not an open-market buy. It is coded as a grant, award, or other acquisition, meaning the CEO received shares as compensation rather than purchasing them in the market.

How many WHWK shares does the CEO hold after this Form 4 grant?

After receiving the 51,021-share grant, David James Lennon directly holds 569,643 shares of Whitehawk Therapeutics Common Stock. This total reflects his position immediately following the reported equity compensation transaction.

What price per share was used for the WHWK CEO stock grant?

The Form 4 reports an indicated value of $3.92 per share for the 51,021-share grant. This figure is typically a fair value or reference price used for reporting, not evidence of an open-market trade.

Does the WHWK CEO Form 4 include any stock sales or disposals?

The Form 4 does not report any stock sales or disposals. It only shows an acquisition coded as a grant, award, or other acquisition of 51,021 shares of Common Stock, increasing the CEO’s direct holdings.